The First and Only Novel Targeted Therapy Approved for mCRC – August 6th
Loading Map....
The First and Only Novel Targeted Therapy Approved for mCRC, Regardless of Mutation Status, in More Than a Decade1-3
Featuring: Farshid Dayyani, MD, PhD, Physician, University of California, Irvine, Orange CA
Hosted by: Matt Campbell, Oncology Territory Manager, Takeda
Location: Vina Enoteca, 700 Welch Road, Palo Alto, CA 94304, (650) 646-3477
Date: August 6th, 2025 at 6:15 PM
Register here: matt.campbell@tekeda.com | (415) 640-2713
RSVP by 07/31/2025
Meeting Code: 10178